EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review

Amna Gameil, Rola Ghasoub, Neda Jafari, Laila Shafei, Maria Benkhadra, Saad Laws, Anas Hamad, Iman Sabet, Dragana Milojkovic, Liam Fernyhough

Oncology · 2026

DOI: 10.1159/000550346 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Oncology, 2026. Verfasst von Amna Gameil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar, agamil@ham…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognosis of chronic myeloid leukemia (CML) has been revolutionized in recent decades with tyrosine kinase inhibitors (TKIs). Yet, comorbidities that require anticoagulation therapy pose a challenge in CML management because of the scarcity of evidence on the optimal drug combinations. This systematic review (SR) aimed to summarize the efficacy and safety considerations for the concomitant use of anticoagulants with different TKIs in CML and investigate their potential drug interactions.

Methods

A comprehensive search strategy was used, employing Medical Subject Headings and free-text terms across databases including PubMed (via OVID), Medline (via OVID), Embase (via OVID), and Web of Science. Members of the research team independently screened the titles and abstracts for eligibility based on predefined inclusion and exclusion criteria. Data extraction was then performed using a standardized form to record the studies’ characteristics, the TKIs and anticoagulants used, and the safety outcomes. Two reviewers independently assessed study quality using the Critical Appraisal Skills Program (CASP) checklists and the Joanna Briggs Institute (JBI) tool for case reports.

Results

The search yielded 406 studies, of which 13 met the inclusion criteria for reporting real-world safety data in adults receiving TKIs with anticoagulants. Overall, the combinations of TKIs with anticoagulants like ponatinib with apixaban and imatinib with warfarin had no major bleeding complications. The pharmacokinetic findings suggested some interaction variability, particularly between nilotinib and warfarin, but overall anticoagulant use appeared safe in the studied populations across various indications.

Conclusion

This is the first SR to address a critical gap in the literature by evaluating the safety profiles of various TKIs in combination with different anticoagulants. The findings from cohort studies highlighted the feasibility of concomitant use of anticoagulants and TKIs in CML patients, with close monitoring of potential adverse events and drug interactions. PROSPERO registration number was CRD42024528737.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAnticoagulantsHumansDrug InteractionsPyrazolesImatinib MesylateTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

AnticoagulationChronic myeloid leukemiaTyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsAnticoagulantsPyrazolesImatinib MesylateTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar, agamil@hamad.qa.
  • College of Medicine, Qatar University, Doha, Qatar, agamil@hamad.qa.
  • Department of Medicine, Weill Cornell, Doha, Qatar, agamil@hamad.qa.
  • Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar, rghasoub@hamad.qa.
  • Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Health Sciences Library, Weill Cornell Medicine, Doha, Qatar.

Zitieren

APA

Gameil, A., Ghasoub, R., Jafari, N., Shafei, L., Benkhadra, M., Laws, S., Hamad, A., Sabet, I., Milojkovic, D., & Fernyhough, L. (2026). Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review. Oncology. https://doi.org/10.1159/000550346

Vancouver

Gameil A, Ghasoub R, Jafari N, Shafei L, Benkhadra M, Laws S, et al. Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review. Oncology. 2026. doi:10.1159/000550346

BibTeX
@article{Gameil2026,
  author = {Gameil, Amna and Ghasoub, Rola and Jafari, Neda and Shafei, Laila and Benkhadra, Maria and Laws, Saad and Hamad, Anas and Sabet, Iman and Milojkovic, Dragana and Fernyhough, Liam},
  title = {Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review},
  journal = {Oncology},
  year = {2026},
  doi = {10.1159/000550346}
}
Kostenlos starten →